UroGen Pharma Ltd. — Director's Dealing 2020

Sep 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-09-09

Reporting Person: Smith Jason Drew (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-09	Employee Stock Option (right to buy)	$21.38	A	60000	Acquired	2030-09-08	Ordinary Shares (60000)	Direct
2020-09-09	Restricted Stock Unit	$	A	25000	Acquired		Ordinary Shares (25000)	Direct

Footnotes

F1: 33.33% of the shares underlying the stock option will vest on September 9, 2021, 33.33% of the remaining shares underlying the stock option will vest on September 9, 2022, and 33.34% of the remaining shares shares underlying the stock option will vest on September 9, 2023.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F3: 33.33% of the restricted stock units ("RSUs") will vest on September 9, 2021, 33.33% of the remaining RSUs will vest on September 9, 2022, and 33.34% of the remaining RSUs will vest on September 9, 2023.